Niosome-based delivery systems for olanzapine: Formulation, characterisation, and kinetic evaluation.

IF 1.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Samiah Alhabardi, Basmah Aldosari, Gadah Al-Hamoud, Shog Moahmmed Alali, Reema Al Khbiah, Lama Albulayhi, Wedad Sarawi, Naifa Alenazi
{"title":"Niosome-based delivery systems for olanzapine: Formulation, characterisation, and kinetic evaluation.","authors":"Samiah Alhabardi, Basmah Aldosari, Gadah Al-Hamoud, Shog Moahmmed Alali, Reema Al Khbiah, Lama Albulayhi, Wedad Sarawi, Naifa Alenazi","doi":"10.2478/acph-2025-0026","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigates the development and characterisation of niosome-based delivery systems for olanzapine, an antipsychotic drug. Niosomes were prepared using various grades of Span surfactants (Span 60, Span 40, and Span 20) in combination with cholesterol at different ratios. The formulations were characterised in terms of particle size, polydispersity index, zeta potential, and encapsulation efficiency. Results showed an inverse relationship between surfactant hydrophilic-lipophilic balance (HLB) values and niosome size, with Span 60 producing the smallest vesicles. Optimal formulations were achieved with a 1:1 ratio of surfactant to cholesterol. Span 60 niosomes exhibited the highest encapsulation efficiency (up to 81 ± 2.5 %) and the most negative zeta potential, indicating superior stability. <i>In vitro</i> release studies demonstrated sustained release profiles for all niosomal formulations compared to the free drug, with Span 60 formulations showing the slowest release rates. Release kinetics analysis revealed a Fickian diffusion-controlled mechanism best described by the Korsmeyer-Peppas model. These findings suggest that niosomal formulations, particularly those based on Span 60, offer a promising approach for improving olanzapine delivery, potentially enhancing its bioavailability and therapeutic efficacy in the treatment of psychiatric disorders.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2025-0026","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

This study investigates the development and characterisation of niosome-based delivery systems for olanzapine, an antipsychotic drug. Niosomes were prepared using various grades of Span surfactants (Span 60, Span 40, and Span 20) in combination with cholesterol at different ratios. The formulations were characterised in terms of particle size, polydispersity index, zeta potential, and encapsulation efficiency. Results showed an inverse relationship between surfactant hydrophilic-lipophilic balance (HLB) values and niosome size, with Span 60 producing the smallest vesicles. Optimal formulations were achieved with a 1:1 ratio of surfactant to cholesterol. Span 60 niosomes exhibited the highest encapsulation efficiency (up to 81 ± 2.5 %) and the most negative zeta potential, indicating superior stability. In vitro release studies demonstrated sustained release profiles for all niosomal formulations compared to the free drug, with Span 60 formulations showing the slowest release rates. Release kinetics analysis revealed a Fickian diffusion-controlled mechanism best described by the Korsmeyer-Peppas model. These findings suggest that niosomal formulations, particularly those based on Span 60, offer a promising approach for improving olanzapine delivery, potentially enhancing its bioavailability and therapeutic efficacy in the treatment of psychiatric disorders.

奥氮平的niosome基给药系统:配方、表征和动力学评价。
本研究调查了一种抗精神病药物奥氮平的niosome为基础的递送系统的发展和特征。用不同等级的Span表面活性剂(Span 60、Span 40和Span 20)与胆固醇按不同比例混合制备了膜小体。从粒径、多分散性指数、zeta电位和包封效率等方面对配方进行了表征。结果表明,表面活性剂亲水性-亲脂性平衡(HLB)值与囊体大小呈反比关系,其中Span 60产生的囊泡最小。当表面活性剂与胆固醇的比例为1:1时,得到了最佳配方。Span 60纳米体的包封效率最高(达81±2.5%),zeta负电位最高,具有较好的稳定性。体外释放研究表明,与游离药物相比,所有niosomal制剂的缓释谱显示,Span 60制剂的释放速度最慢。释放动力学分析揭示了一个由Korsmeyer-Peppas模型最能描述的Fickian扩散控制机制。这些发现表明,niosomal formulations,特别是基于Span 60的niosomal formulations,提供了一种有希望的方法来改善奥氮平的递送,潜在地提高其生物利用度和治疗精神疾病的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmaceutica
Acta Pharmaceutica PHARMACOLOGY & PHARMACY-
CiteScore
5.20
自引率
3.60%
发文量
20
审稿时长
>12 weeks
期刊介绍: AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信